Frontlight ResearchEarly access
Taking people in United StatesPhase 2/3
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
Key facts
- Who runs it
- Nationwide Children's Hospital
- Where
- Akron, Ann Arbor, Atlanta, Aurora, Birmingham, Charleston, Cincinnati, Cleveland, Columbus, Dallas, Detroit, Durham, Hershey, Houston, Indianapolis, Kansas City, Little Rock, Los Angeles, Milwaukee, Minneapolis, Oakland, Orange, Philadelphia, Pittsburgh, Richmond, Sacramento, Salt Lake City, San Antonio, San Diego, San Francisco, and Washington D.C., United StatesSee the 32 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 500 people, planned
- Started
- 14 Jun 2022
- Expected to end
- 31 Aug 2028
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Anakinra
- Placebo
- Record updated
- 13 March 2026
Who can take part
- Age
- 1 day to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- ≥ 40 weeks corrected gestational age to < 18 years; AND
- Admission to the PICU or CICU; AND
- Onset of ≥ 2 new organ dysfunctions within the last 3 calendar days (compared to pre-sepsis baseline) as measured by the modified Proulx criteria; AND
- Documented or suspected infection as the MODS inciting event
Who cannot take part
- Current or prior diagnosis of hemophagocytic lymphohistiocytosis or macrophage activation syndrome; OR
- Receipt of anakinra within the previous 28 days; OR
- Previous enrollment in the TRIPS study
- Moribund condition in which the patient is unlikely to survive the next 48 hours in opinion of the clinical team; OR
- Known allergy to anakinra, or E. coli-derived products; OR
- Peripheral white blood cell count < 1,000 cells/mm3 as the result of myeloablative therapy OR receipt of myeloablative therapy within the previous 14 days; OR
- Weight <3kg; OR
- Limitation of care order at the time of screening; OR
- Patients at high likelihood of progression to brain death in opinion of the clinical team; OR
- Known pregnancy; OR
- Lactating females; OR
- Resolution of MODS by MODS Day 2; OR
Where in United States
- Akron Children's HospitalAkron, United StatesContact: Christopher Page-Goertz, MDTaking people
- CS Mott Children's HospitalAnn Arbor, United StatesContact: Michael QuasneyTaking people
- Children's Hospital of AtlantaAtlanta, United StatesContact: Jocelyn Grunwell, MD, PhDTaking people
- Children's Hospital ColoradoAurora, United StatesContact: Eva NozikTaking people
- Children's of AlabamaBirmingham, United StatesContact: Michele Kong, MDTaking people
- Medical University of South CarolinaCharleston, United StatesContact: John CostelloTaking people
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Natalja Stanski, MDTaking people
- Rainbow Babies and Children's HospitalCleveland, United StatesContact: Kenneth RemyTaking people
- Nationwide Children's HospitalColumbus, United StatesContact: Mark HallTaking people
- University of Texas, SouthwesternDallas, United StatesContact: Matthew BorgmanTaking people
- Children's Hospital of MichiganDetroit, United StatesContact: Kathleen Meert, MDTaking people
- Duke UniversityDurham, United StatesContact: Christoph HornikTaking people
- Pennsylvania State UniversityHershey, United StatesContact: Neal ThomasTaking people
- Texas Children's HospitalHouston, United StatesContact: Ayse ArikanTaking people
- Riley Children's HospitalIndianapolis, United StatesContact: Daniel Cater, MDTaking people
- Mercy Children's HospitalKansas City, United StatesContact: Yong HanTaking people
- Arkansas Children's HospitalLittle Rock, United StatesContact: Ronald SandersTaking people
- Children's Hospital of Los AngelesLos Angeles, United StatesContact: Robinder KhemaniTaking people
- Medical College of WisconsinMilwaukee, United StatesContact: Nathan ThompsonNot yet recruiting
- Children's Hospital of MinnesotaMinneapolis, United StatesContact: Alberto OriolesNot yet recruiting
- University of MinnesotaMinneapolis, United StatesContact: Marie SteinerTaking people
- Benioff Children's Hospital - OaklandOakland, United StatesContact: Natalie CvijanovichTaking people
- Children's Hospital of Orange CountyOrange, United StatesContact: Adam SchwarzNot yet recruiting
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Julie FitzgeraldTaking people
- Children's Hospital of PittsburghPittsburgh, United StatesContact: Joseph CarcilloTaking people
- Virginia Commonwealth UniversityRichmond, United StatesContact: Nikki Miller-FergusonTaking people
- University of California - DavisSacramento, United StatesContact: MoonJoo Han, MDTaking people
- Primary Children's HospitalSalt Lake City, United StatesContact: Jill SweneyTaking people
- Children's Hospital of San AntonioSan Antonio, United StatesContact: Kirstin HenleyTaking people
- Rady Children's HospitalSan Diego, United StatesContact: Nicole CoufalTaking people
- Benioff Children's Hospital - Mission BaySan Francisco, United StatesContact: Patrick McQuillenTaking people
- Children's National Medical CenterWashington D.C., United StatesContact: Sonali BasuTaking people
About the trial
What the trial wants to find out
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
The 5 groups in the trial
- Anakinra 4 mg/kg/dayExisting treatment, for comparison
IV Anakinra 4mg/kg/day x 7 days
Treatment: Anakinra
- Anakinra 8 mg/kg/dayExisting treatment, for comparison
IV Anakinra 8 mg/kg/day x 7 days
Treatment: Anakinra
- Anakinra 12 mg/kg/dayExisting treatment, for comparison
IV Anakinra 12 mg/kg/day x 7 days
Treatment: Anakinra
- Anakinra 16 mg/kg/dayExisting treatment, for comparison
IV Anakinra 16 mg/kg/day x 7 days
Treatment: Anakinra
- PlaceboPlacebo, for comparison
IV placebo x 7 days
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (TRIPS)
- Publications
- The Design of Nested Adaptive Clinical Trials of Multiple Organ Dysfunction Syndrome Children in a Single Study.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2023
- Record updated
- 13 March 2026